Value through Innovation22 December 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation

- Not intended for media in the UK, the US or Canada

Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"

- For Non-U.S. and Non-UK media

Boehringer Ingelheim responds to FDA warning letter


Wireless Pill Bottle Wins Healthcare Innovation World Cup


Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response

- For Media outside the U.S., Canada and UK

Change in the Board of Managing Directors at Boehringer Ingelheim


ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment


ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC

- For non U.S. Media Only

Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases


Boehringer Ingelheim Announces a Strong 2012 Performance in China


Boehringer Ingelheim consistently continues growth phase in financial year 2012


Boehringer Ingelheim announces results from one of its HCV Phase III trials:
Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1
hepatitis C

- For media outside USA, UK and Canada only

Innovative treatment for canine epilepsy: European approval granted for Boehringer Ingelheim’s Pexion®


FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)

- For media outside of the US, the UK & Canada only

Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin*

- EX US & UK Medical Media Only

Boehringer Ingelheim and Lilly initiate MARLINA-T2D™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria

- For Non-U.S. and Non-U.K. Media

Boehringer Ingelheim Animal Health sponsors PCV2 research projects with more than 400,000 euro


American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013

- For Non-US, Non-UK & Non-Canadian Media Only